18F-FDG PET/MRI 在肺部恶性肿瘤检测中的系统评价与荟萃分析
该系统评价与荟萃分析纳入43项研究共1278例患者,评估18F-FDG PET/MRI对肺部恶性肿瘤的检测效能。汇总敏感度为96%(95%CI:84,99),特异度为100%(95%CI:98,100),与18F-FDG PET/CT相当;使用对比剂或扩散加权成像方案的研究敏感度显著更高。
要点
- 18F-FDG PET/MRI对肺部恶性病变检测敏感度96%、特异度100%,与PET/CT相当。
- 在PET/MRI方案中加入对比剂或扩散加权成像可显著提高敏感度。
- 日常阅片可将PET/MRI作为肺部恶性肿瘤检测的可靠手段,注意方案组成影响诊断效能。
核心结论
- 18F-FDG PET/MRI检测肺部恶性病变准确,与18F-FDG PET/CT相当,采用对比剂或扩散加权成像等先进采集方案时敏感度显著提高。
研究设计与样本
- 系统评价与荟萃分析,检索Scopus、Web of Science和PubMed至2021年12月31日,纳入43项原始研究共1278例患者。
- 纳入标准为检测肺部恶性病变、与有效参考标准比较、提供荟萃分析所需数据。
- 采用分层法合并效能,双变量模型计算汇总点及95%CI,分层汇总受试者工作特征模型绘制SROC曲线并计算AUC,Higgins I2统计量和Cochran Q检验评估异质性。
诊断标准与关键数值
- 18F-FDG PET/MRI汇总敏感度96%(95%CI:84,99),汇总特异度100%(95%CI:98,100)。
- 18F-FDG PET/CT汇总敏感度99%(95%CI:61,100),汇总特异度99%(95%CI:94,100),与PET/MRI相当。
- 荟萃回归显示使用对比剂(P = .03)和扩散加权成像(P = .04)作为肺部18F-FDG PET/MRI方案组成部分的研究敏感度显著更高。
临床应用与阅片要点
- 肺部恶性肿瘤检测中PET/MRI可作为PET/CT的替代选择,阅片时应关注方案是否包含对比剂或扩散加权成像以优化敏感度。
局限性
- 纳入研究间异质性采用I2和Q检验评估,但原文未具体报告异质性大小及来源。
- 检索截止2021年12月31日,可能未涵盖后续发表的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background There have been conflicting results regarding fluorine 18-labeled fluorodeoxyglucose (18F-FDG) PET/MRI diagnostic performance in lung malignant neoplasms. Purpose To evaluate the diagnostic performance of 18F-FDG PET/MRI for the detection of pulmonary malignant neoplasms. Materials and Methods A systematic search was conducted within the Scopus, Web of Science, and PubMed databases until December 31, 2021. Published original articles that met the following criteria were considered eligible for meta-analysis: (a) detecting malignant lesions in the lung, (b) comparing 18F-FDG PET/MRI with a valid reference standard, and (c) providing data for the meta-analytic calculations. A hierarchical method was used to pool the performances. The bivariate model was used to find the summary points and 95% CIs. The hierarchical summary receiver operating characteristic model was used to draw the summary receiver operating characteristic curve and calculate the area under the curve. The Higgins I2 statistic and Cochran Q test were used for heterogeneity assessment. Results A total of 43 studies involving 1278 patients met the inclusion criteria and were included in the meta-analysis. 18F-FDG PET/MRI had a pooled sensitivity and specificity of 96% (95% CI: 84, 99) and 100% (95% CI: 98, 100), respectively. 18F-FDG PET/CT had a pooled sensitivity and specificity of 99% (95% CI: 61, 100) and 99% (95% CI: 94, 100), respectively, which were comparable with those of 18F-FDG PET/MRI. At meta-regression, studies in which contrast media (P = .03) and diffusion-weighted imaging (P = .04) were used as a part of a pulmonary 18F-FDG PET/MRI protocol showed significantly higher sensitivities. Conclusion Fluorine 18-labeled fluorodeoxyglucose (18F-FDG) PET/MRI was found to be accurate and comparable with 18F-FDG PET/CT in the detection of malignant pulmonary lesions, with significantly improved sensitivity when advanced acquisition protocols were used. © RSNA, 2023 Supplemental material is available for this article.
引用
- Mirshahvalad, Metser, Basso Dias, et al. 18F-FDG PET/MRI in Detection of Pulmonary Malignancies: A Systematic Review and Meta-Analysis. Radiology. 2023. PMID: 36692397. doi:10.1148/radiol.221598
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。